7,12-Dimethylbenz(a)anthracene
Names | |
---|---|
IUPAC name
7,12-Dimethylbenzo[a]phenanthrene | |
Other names
7,12-Dimethylbenzanthracene; 7,12-Dimethyltetraphene; 1,4-Dimethyl-2,3-benzophenanthrene | |
Identifiers | |
57-97-6 | |
3D model (Jmol) | Interactive image |
ChEBI | CHEBI:254496 |
ChEMBL | ChEMBL329673 |
ChemSpider | 5779 |
ECHA InfoCard | 100.000.326 |
PubChem | 6001 |
| |
| |
Properties | |
C20H16 | |
Molar mass | 256.35 g·mol−1 |
Melting point | 122 to 123 °C (252 to 253 °F; 395 to 396 K) |
Hazards | |
Main hazards | T (Toxic) |
R-phrases | R45 R22 |
S-phrases | S53 S36/37 S45 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
7,12-Dimethylbenz[a]anthracene (DMBA) is an immunosuppressor and a powerful organ-specific laboratory carcinogen.[2] DMBA is widely used in many research laboratories studying cancer. DMBA serves as a tumor initiator. Tumor promotion can be induced with treatments of 12-O-tetradecanoylphorbol-13-acetate (TPA) in some models of two-stage carcinogenesis.[3] This allows for a greatly accelerated rate of tumor growth, making many cancer studies possible.
References
- ↑ 7,12-Dimethylbenz(a)anthracene at Sigma-Aldrich
- ↑ Miyata M; Furukawa M; Takahashi K; Gonzalez FJ; Yamazoe Y (2001). "Mechanism of 7, 12-Dimethylbenz[a]anthracene-Induced Immunotoxicity: Role of Metabolic Activation at the Target Organ". Jpn J Pharmacol. 86: 302–309. doi:10.1254/jjp.86.302.
- ↑ Sung YM; He G; Fischer, SM (2005). "Lack of Expression of the EP2 but not EP3 Receptor for Prostaglandin E2 Results in Suppression of Skin Tumor Development". Cancer Res. 65: 9304–9311. doi:10.1158/0008-5472.can-05-1015.
This article is issued from Wikipedia - version of the 5/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.